CN104370913A - Intraocular tension reducing compound and preparation method and use thereof - Google Patents
Intraocular tension reducing compound and preparation method and use thereof Download PDFInfo
- Publication number
- CN104370913A CN104370913A CN201410021966.3A CN201410021966A CN104370913A CN 104370913 A CN104370913 A CN 104370913A CN 201410021966 A CN201410021966 A CN 201410021966A CN 104370913 A CN104370913 A CN 104370913A
- Authority
- CN
- China
- Prior art keywords
- compound
- propyl
- preparation
- acceptable salt
- analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an intraocular tension reducing compound, a pharmaceutically acceptable salt and an analogue thereof, a pharmaceutical composition prepared from the intraocular tension reducing compound, the pharmaceutically acceptable salt and the analogue, and use of the intraocular tension reducing compound, the pharmaceutically acceptable salt and the analogue in preparation of intraocular tension reducing drugs, the invention discloses a preparation method and use of the intraocular tension reducing compound and the pharmaceutical composition, the intraocular tension reducing animal experiment of the intraocular tension reducing compound is performed, and the compound has very obvious intraocular tension reducing effects.
Description
Technical field
The present invention relates to a class and reduce the compound of intraocular pressure and pharmacologically acceptable salt thereof and its analogue, the pharmaceutical composition prepared by above-claimed cpd and pharmacologically acceptable salt thereof and its analogue, and described compound or pharmaceutically acceptable salt thereof and analogue thereof reduce the purposes in the medicine of intraocular pressure in preparation.
Background technology
Intraocular pressure (IOP) is a kind of eye disease endangering whole world human health because a variety of causes raises, and the main manifestations of patient is intraocular pressure short-term or increases for a long time.Because intraocular pressure rising can cause the vision loss of non-reversibility, therefore this is a kind of very serious diseases causing blindness.
Current scientific circles there is no final conclusion for the pathogenic factor reducing intraocular pressure, are known as and are caused by many reasons, not very good in the result for the treatment of of the medicine reducing intraocular pressure clinically at present.Because PATIENT POPULATION is very large and harm is very large, need a kind of effective medicine badly and treat.
The present inventor has prepared one group of compound and similar compound thereof or its pharmacologically acceptable salt, and this group compound and similar compound thereof or its pharmacologically acceptable salt reduce on the medicine of intraocular pressure in preparation beyond thought outstanding effect.
Summary of the invention
The preparation that the invention provides one group of compound and similar compound or its pharmacologically acceptable salt and the novelty teabag reduced in preparation in the medicine of intraocular pressure thereof.
Technical scheme of the present invention is as follows:
One compounds or its pharmacologically acceptable salt and analogue thereof, the structure of described compound is as follows:
Wherein R1 is selected from methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, benzyl; R2 is selected from methyl, ethyl, n-propyl, sec.-propyl, methoxyl group, oxyethyl group, propoxy-; R3 is selected from hydrogen, methyl, ethyl, n-propyl, sec.-propyl, methoxyl group, oxyethyl group, positive propoxy.
The present invention has specifically prepared following 2 compounds:
Compound (A);
Compound (B);
The synthetic route of compound of the present invention is as follows:
Wherein R1 is selected from methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, benzyl; R2 is selected from methyl, ethyl, n-propyl, sec.-propyl, methoxyl group, oxyethyl group, propoxy-; R3 is selected from hydrogen, methyl, ethyl, n-propyl, sec.-propyl, methoxyl group, oxyethyl group, positive propoxy.
Compound or pharmaceutically acceptable salt thereof of the present invention and analogue thereof reduce the purposes in the medicine of intraocular pressure in preparation, are specially the intraocular pressure rising that can reduce and be caused by a variety of causes.
Compound of the present invention and analogue thereof or its pharmacologically acceptable salt can be prepared into through topical, gastrointestinal administration or the various preparations of parenteral administration.Described preparation comprises ordinary preparation, controlled release preparation, targeting preparation etc.Described local administration preparation is powder injection, aqueous injection, microball preparation, nanometer formulation, Liposomal formulation, dendrimer preparation, polyethyleneglycol modified preparation, aqueogel etc. through organ administration.Described parenterals is the formulation of suitable intravenous injection, intramuscular injection, subcutaneous injection, bone marrow injection, transdermal administration, mucosa delivery and inhalation.
The present inventor studies discovery: this compounds can greatly alleviate Bulbi hypertonia symptom, and from the result of pharmacodynamic experiment, the effect of the step-down of this compounds exceeds the medicine of current clinical application.The exploitation of this new compound is by for playing very large effect to the recovery of following Bulbi hypertonia patient.Painful for releasing sufferer, the quality of life improving patient is significant.
Accompanying drawing explanation
Fig. 1: the nuclear magnetic spectrum of compound (A).
Fig. 2: the nuclear magnetic spectrum of compound (B).
Embodiment
preparation embodiment
The preparation of preparation embodiment 1(compd A and compd A 6)
Compd A 1 and a1, K
2cO
3, CH
3cOCH
3backflow generates compd A 2, by A2 and a2, a3 is together placed in distilling flask at triethylamine, in ethanol, backflow generates compound A-13, compound A-13 normal-temperature reaction in the aqueous ethanolic solution of sodium hydroxide generates compd A 4 in 12 hours, compd A 4 is under sodium borohydride catalysis, and in ethanolic soln, normal temperature generates compound A-45, and compound A-45 and a4 generate A6 under 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride and I-hydroxybenzotriazole catalysis.
The preparation of preparation embodiment 2(compd B and compound B-26)
Compound B-11 and b1, K
2cO
3, CH
3cOCH
3backflow generates compd B 2, by B2 and b2, b3 is together placed in distilling flask at triethylamine, in ethanol, backflow generates compd B 3, compd B 3 normal-temperature reaction in the aqueous ethanolic solution of sodium hydroxide generates compd B 4 in 12 hours, compd B 4 is under sodium borohydride catalysis, and in ethanolic soln, normal temperature generates compd B 5, and compd B 5 and b4 generate B6 under 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride and I-hydroxybenzotriazole catalysis.
Preparation containing compd A injection:
1. get common 50mg and 100mg formula (A) compound of N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer mix in water for injection and make it to dissolve;
2. mixing first uses 0.45um millipore filtration coarse filtration after dissolving after stable, then uses 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other freeze-drying therapeutical agent and auxiliary materials;
4. procedural freeze-drying is carried out;
5. pyrogen, aseptic, the corresponding inspection such as visible foreign matters, particulate matter is carried out, stand-by after all meeting the requirements.
Preparation containing compd B injection:
1. get common 50mg and 200mg formula (B) compound of N.F,USP MANNITOL, phosphatide, glycerine, cyclodextrin derivative, dimethyl sulfoxide (DMSO) and poloxamer mix in water for injection and make it to dissolve;
2. mixing first uses 0.45um millipore filtration coarse filtration after dissolving after stable, then uses 0.2um filtering with microporous membrane;
3. be distributed into little cillin bottle, add other freeze-drying therapeutical agent and auxiliary materials;
4. procedural freeze-drying is carried out;
5. pyrogen, aseptic, the corresponding inspection such as visible foreign matters, particulate matter is carried out, stand-by after all meeting the requirements.
effect example
Compound (A-B) is to the Experiment on therapy of high intraocular pressure in rats
1.1 laboratory animal and grouping
Experiment adopts Thirty male rats, about body weight 220g.Before modeling, by animal random packet: i.e. blank group; Model group; Compound (A-B) group, is administered once every 5 days intravitreal injections, dosage 0.1mg injection/kg; Positive drug group selection pilocarpine eye drop, every day is administered once, one time one.All administrations continue 15 days.
The foundation of 1.2 animal models
Abdominal injection rat 4% Chloral Hydrate (200mg.kg-1) before experiment, then uses the lignocaine toponarcosis cornea of rats of 1%.During preparing high intraocular pressure model, keep every half an hour abdominal injection 4% Chloral Hydrate 0.2 milliliter make the state of animal continuous narcosis.Adopt pulley-suture system that rat right eye intraocular pressure is raised, left side eyeball contrasts simultaneously.Be respectively an identical heavy counterweight by surgical sutures two ends, hitch a circle in the middle of suture for around after rat canthus limbus of sclera 2 millimeters, the counterweight at two ends is exerted pressure to rat eye continually and steadily by pulley.It is 20 grams that counterweight is exerted pressure, and continuous 6 hours, causes high intraocular pressure in rats model.Raise after administration and within 15 days, measure rathole pressure and record.
1.3 experimental result
Experimental result is in table 1
The intraocular pressure result (mmHg, n=10) of the rat under drug treatment respectively organized by table 1
| Group | Value before medicine | 15 days |
| Normal group | 14.2±1.8 | 14.3±1.6 |
| Model group | 28.2±1.3 | 29.0±1.6 |
| Medicine A group | 28.3±1.3 | 15.2±1.4** |
| Medicine B group | 28.0±1.5 | 15.0±1.4** |
| Positive drug eye drop group | 28.0±1.4 | 21.7±1.3* |
* P<0.05**P<0.01 is compared with model group
Compd A-E is to the ocular hypertensive Experiment on therapy of rabbit
2.1 laboratory animal and grouping
Healthy regular grade rabbit, male and female half and half, about body weight 2.3kg, examination with slitlamp microscope is without anterior ocular segment pathology.Before non-modeling, random selecting experimental rabbit 20, respectively at many point in time measurement rabbit bilateral intraocular pressure record every day.Continuous Observation is after one week, to determine this group experimental rabbit normal intraocular tension scope.Modeling is after 1 week, by animal pattern random packet: by animal random packet: i.e. blank group; Model group; Compound (A-B) group, is administered once every 5 days intravitreal injections, injection administration 0.5mg injection in every lagophthalmos; VUFB-6453 eye drop is selected in positive drug group selection, and every day is administered once.All administrations continue 15 days.
The foundation of 2.2 animal models
Often organize 10 rabbit cornea of right eye edge, 12 position puncture of anterior chamber, extract aqueous humor 0.2 milliliter out.0.3% carbomer and 0.025% dexamethasone 0.2 milliliter are injected to anterior chamber through puncture orifice, and left eye is contrast eye, and modeling started administration after one week.
2.3 measure intraocular pressure
After animals administer, measure the 15th day intraocular pressure after administration and record with tonometer.
2.4 experimental result
After rabbit modeling, intraocular pressure raises, and the intraocular pressure of each medication therapy groups all raises, the success of display modeling type.After administration, each medicine group raises intraocular pressure all has restraining effect, and wherein to organize effect the most obvious for compound (A-B), and medicine (A-B) is organized result for the treatment of and is all better than positive drug group.
Lagophthalmos pressure result (n=10) under drug treatment respectively organized by table 2
| Group | Value before medicine | 15 days |
| Model group | 36.0±5.0 | 28.0±5.1 |
| Medicine A group | 36.2±5.0 | 14.9±4.3** |
| Medicine B group | 36.1±5.0 | 15.0±4.2** |
| Positive drug eye drop group | 36.2±5.4 | 20.0±4.3* |
* P<0.05**P<0.01 is compared with model group
Comprehensive above-mentioned experimental result is reached a conclusion: compound (A), and medicine prepared by (B) all plays the effect reducing intraocular pressure preferably.
Claims (7)
1. a compounds or its pharmacologically acceptable salt and analogue thereof, the structure of described compound is as follows:
Wherein R
1be selected from methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, benzyl; R
2be selected from methyl, ethyl, n-propyl, sec.-propyl, methoxyl group, oxyethyl group, propoxy-; R3 is selected from hydrogen, methyl, ethyl, n-propyl, sec.-propyl, methoxyl group, oxyethyl group, positive propoxy.
2. compound or pharmaceutically acceptable salt thereof according to claim 1 and analogue thereof, it is selected from following compound:
Compound (A);
Compound (B).
3. the preparation method of compound described in claim any one of claim 1-2, is characterized by and synthesize according to following route:
Wherein R1 is selected from methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, benzyl; R2 is selected from methyl, ethyl, n-propyl, sec.-propyl, methoxyl group, oxyethyl group, propoxy-; R3 is selected from hydrogen, methyl, ethyl, n-propyl, sec.-propyl, methoxyl group, oxyethyl group, positive propoxy.
4. compound or pharmaceutically acceptable salt thereof described in any one of claim 1-3 and analogue thereof reduce the purposes in the medicine of intraocular pressure in preparation.
5. purposes according to claim 4, is characterized in that the effect of described reduction intraocular pressure is specially the intraocular pressure rising that can reduce and be caused by a variety of causes.
6. comprise the pharmaceutical composition of compound or pharmaceutically acceptable salt thereof any one of claim 1-5 and analogue thereof, it is characterized in that this pharmaceutical composition to be prepared into ordinary preparation, controlled release preparation or targeting preparation.
7. the pharmaceutical composition of claim 6, described compound and pharmacologically acceptable salt thereof are prepared into through topical with its analogue, gastrointestinal administration or the various preparations of parenteral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410021966.3A CN104370913A (en) | 2013-01-18 | 2014-01-18 | Intraocular tension reducing compound and preparation method and use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100249359 | 2013-01-18 | ||
| CN201310024935 | 2013-01-18 | ||
| CN201410021966.3A CN104370913A (en) | 2013-01-18 | 2014-01-18 | Intraocular tension reducing compound and preparation method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104370913A true CN104370913A (en) | 2015-02-25 |
Family
ID=52550146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410021966.3A Pending CN104370913A (en) | 2013-01-18 | 2014-01-18 | Intraocular tension reducing compound and preparation method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104370913A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104387391A (en) * | 2013-01-18 | 2015-03-04 | 韩冰 | Protease inhibitor and preparation method and application thereof |
-
2014
- 2014-01-18 CN CN201410021966.3A patent/CN104370913A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104387391A (en) * | 2013-01-18 | 2015-03-04 | 韩冰 | Protease inhibitor and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| BAGGA, V.等: "A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors", 《SAR AND QSAR IN ENVIRONMENTAL RESEARCH》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017317950B2 (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
| JP2016512562A (en) | Microemulsion topical delivery platform | |
| JP2017519813A (en) | Topical formulations and uses thereof | |
| CN104628657A (en) | Class of compounds for treating ischemic brain damage and purpose thereof | |
| CN103845330A (en) | Compound for reducing intraocular pressure and application thereof | |
| CN104119338A (en) | Compounds reducing intraocular pressure, and preparation method and application thereof | |
| JP2023099169A (en) | Pharmaceuticals of multi-target inhibitors | |
| CN104151303A (en) | Intraocular tension reducing compound and preparation method and use thereof | |
| CN103896899A (en) | Compounds for reducing intraocular pressure and preparation method and application thereof | |
| CN103848837A (en) | Compound for reducing intraocular pressure and application thereof | |
| CN103845321A (en) | Compound for reducing intraocular pressure and application thereof | |
| CN103845334A (en) | Compound for reducing intraocular pressure and application thereof | |
| CN104119339B (en) | One kind reduces compound of intraocular pressure and its production and use | |
| CN104370938A (en) | Intraocular tension reducing compound and preparation method and use thereof | |
| CN104370913A (en) | Intraocular tension reducing compound and preparation method and use thereof | |
| CN104370824A (en) | Intraocular tension reducing compound and preparation method and use thereof | |
| CN103848782A (en) | Application of compound to preparation of drugs for treating glaucoma | |
| CN104370882A (en) | Intraocular tension reducing compound and preparation method and use thereof | |
| TW202133845A (en) | An ophthalmic composition for preventing or treating eye disease | |
| CN103800340A (en) | Compounds for treating glaucoma and application thereof | |
| CN103800327A (en) | Compounds for treating glaucoma and application thereof | |
| CN103864653A (en) | Compounds for reducing intraocular pressure and use thereof | |
| CN104370889A (en) | Intraocular tension reducing compound and preparation method and use thereof | |
| CN103804298A (en) | Compounds for treating glaucoma and application thereof | |
| CN104721820A (en) | Application of bispecific monoclonal antibody to treatment of uveitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150225 |